Michael Mullan
Principal investigator, leads ARCHER PHARMACEUTICALS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$2.4MFederal grants as PI3 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $2.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 12, 2021 | NIH | STTR Phase II Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease. | $699K | ARCHER PHARMACEUTICALS, INC. |
| May 1, 2020 | NIH | STTR Phase II Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease. | $1.5M | ARCHER PHARMACEUTICALS, INC. with RESEARCH TRIANGLE INSTITUTE |
| Sep 22, 2018 | NIH | STTR Phase II Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease. | $225K | ARCHER PHARMACEUTICALS, INC. |
Peer ranks
Federal funding#807
Awards as PI#822
Patents#273
Companies
- ARCHER PHARMACEUTICALS, INC.Leads (SEC Form D) · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.